The absence of subsequent myasthenic crises after appropriate management suggests that concomitant use of pyridostigmine and azathioprine - both available in SUS - may represent an effective approach to reduce symptoms and improve patients’ quality of life.
Abstract
Background: Myasthenia gravis (MG) is an autoimmune disorder of the neuromuscular junction characterized by muscle weakness due to antibody-mediated attack against acetylcholine receptors (AChR) or associated proteins. International treatment guidelines focus on the adult population and do not provide a specific approach for the juvenile form (JMG), which is even rarer. Consequently, management of young patients is based on adaptation of adult recommendations and on clinical experience of specialists. In Brazil, there is a lack of studies describing the clinical presentation of JMG and its treatment, particularly in the context of the Brazilian Unified Health System (SUS). In this regard, the present study aims to contribute to the understanding of JMG at a tertiary referral center, taking into account therapies available in the public health network. Objective: To characterize the clinical presentation of patients diagnosed with JMG and to describe their therapeutic management. Methods: Retrospective analysis of electronic medical records of patients followed in the neuromuscular diseases outpatient clinic of a tertiary hospital. Inclusion criteria were: symptom onset before 18 years of age; no diagnosis of another neuromuscular condition; and confirmed diagnosis of MG. Informed consent forms were properly signed by patients and/or guardians. The self-reported Myasthenia Gravis Activities of Daily Living scale (MG-ADL) was completed online. Results: Three female patients with generalized JMG were included; their current ages were 10, 14 and 27 years. Ages at symptom onset were 9, 10 and 15 years. Initial signs and symptoms included muscle weakness (3/3), dysphagia (3/3), dysarthria (2/3) and eyelid ptosis (2/3). MG-ADL scores were 0, 5 and 11. Two patients were positive for anti-AChR antibodies, while one was seronegative for both anti-AChR and anti-muscle-specific kinase (anti-MuSK) antibodies. All patients were receiving concomitant anticholinesterase therapy (pyridostigmine), azathioprine and an oral corticosteroid as maintenance therapy or in a gradual tapering regimen. They also required prior rescue therapies (intravenous immunoglobulin and/or plasmapheresis) during myasthenic crises. Thymectomy was performed in two patients, and electroneuromyography demonstrated neuromuscular junction dysfunction. Conclusion: This case series describes the clinical presentation of JMG and adds further descriptions of this rare condition to the Brazilian scientific literature. The MG-ADL scores indicated two patients with controlled disease and one with active disease (>6 points), reflecting differences in treatment response. The absence of subsequent myasthenic crises after appropriate management suggests that concomitant use of pyridostigmine and azathioprine - both available in SUS - may represent an effective approach to reduce symptoms and improve patients’ quality of life.
Background: Myasthenia gravis (MG) is an autoimmune disorder characterized by fluctuating skeletal muscle weakness and fatigability due to impaired neuromuscular transmission. Its clinical expression is heterogeneous. The epidemiology, age at onset, patterns of clinical involvement, and disease trajectory vary across p...
Amanda Vitória Freire de Oliveira, Lucas Grobério Moulim, Manoella Guerra de Albuquerque Bueno et al.· ANPAbstract_CBN26· 0 citations
Focal phenotypes represent uncommon initial presentations of myasthenia gravis and may delay diagnosis, and patients who initially presented with distal upper limb weakness maintained this pattern as the predominant clinical manifestation even after generalization.
Amanda Vitória Freire de Oliveira, Manoella Guerra de Albuquerque Bueno, André Cleriston José dos Santos et al.· ANPAbstract_CBN26· 0 citations
Background: Myasthenia gravis (MG) is an autoimmune disorder characterized by the production of autoantibodies that impair neuromuscular transmission, leading to fluctuating muscle weakness. Although diagnosis and treatment have evolved over recent decades, clinical presentation, laboratory findings, and therapeutic ma...
Julia Fernandes Alves de Oliveira, Maria Clara Magalhães Imbico, L. M. de Matos et al.· ANPAbstract_CBN26· 0 citations
Early recognition and treatment are critical in juvenile myasthenia gravis (JMG), yet pediatric‐specific evidence remains limited. We aimed to describe treatment patterns, remission rates, and predictors in a Canadian cohort.
Tanitnun Paprad, E. Nigro, Z. Aleisa et al.· Muscle and Nerve· 0 citations
A retrospective analysis was conducted on data from 23 patients with IVM hospitalized at the National Center for Maternal and Child Health of the Ministry of Health of the Kyrgyz Republic between 2022 and 2025, finding that the incidence rate increased 2.5-fold compared to the 2015–2022 period.
B. A. Musurkulova, G. Saatova, A. Z. Bolotbekova et al.· Yakut Medical Journal· 0 citations
Background and Objectives Generalized myasthenia gravis (gMG) is a chronic fluctuating neuromuscular disease. Some patients keep experiencing symptoms or adverse events (AEs) despite tailored therapeutic schemes. The aim of this study was to characterize adequately controlled gMG and describe patients' evolution and ou...
D. Reyes-Leiva, Á. Carbayo, A. Vesperinas et al.· Neurology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.